Multiple sclerosis (MS) is a chronic autoimmune disease in which the body’s immune system attacks the myelin sheath — the protective coating around nerve fibres in the brain and spinal cord. For many patients, modern disease-modifying therapies (DMTs) manage the condition well. But for those with highly active, treatment-resistant MS, a more radical approach is now supported by clinical trial evidence: autologous hematopoietic stem cell transplantation (AHSCT). This procedure does not merely suppress the malfunctioning immune system — it effectively dismantles it and regrows it from scratch, using the patient’s own stem cells. Here is what the science says, who may benefit, and what the treatment involves.

What is AHSCT?

AHSCT stands for autologous hematopoietic stem cell transplantation — sometimes called a “stem cell transplant for MS” or simply “hsct ms.” The word autologous means the stem cells come from the patient’s own body, not a donor. Hematopoietic refers to blood-forming stem cells that give rise to every cell in the immune system.

The core idea is a controlled immune reset. By collecting, preserving, and then reinfusing the patient’s stem cells after a high-dose chemotherapy regimen has wiped out the existing immune system, AHSCT allows an entirely new immune repertoire to develop — one that, in many cases, no longer attacks the central nervous system. The goal is not just to slow MS but to halt active inflammatory disease entirely.

How AHSCT works — the four stages

The procedure takes place over several weeks at a specialist transplant centre and involves four distinct phases:

• Mobilisation: Growth factors (typically granulocyte colony-stimulating factor, or G-CSF, sometimes combined with low-dose cyclophosphamide) stimulate the bone marrow to release large numbers of CD34+ stem cells into the bloodstream.
• Harvest (leukapheresis): The circulating stem cells are collected through a process similar to dialysis, filtered from the blood and cryopreserved for later use.
• Conditioning: A high-dose chemotherapy regimen — the intensity varies by protocol (mild, intermediate, or myeloablative) — eliminates the existing immune system. This is the phase that delivers the therapeutic benefit: removing the autoreactive T-cells responsible for MS damage.
• Infusion and engraftment: The preserved stem cells are reinfused. Over approximately two to four weeks, they migrate to the bone marrow and begin rebuilding a new immune system. The patient is hospitalised during this period, typically for three to five weeks in total.

Multiple conditioning protocols are in use worldwide. Intermediate-intensity regimens (such as BEAM-ATG or cyclophosphamide-ATG) have become the most commonly applied, balancing efficacy with a manageable safety profile.

Which MS patients may be eligible?

AHSCT is not for every MS patient. Based on 2024 consensus recommendations from ECTRIMS (the European Committee for Treatment and Research in Multiple Sclerosis) and the European Bone Marrow Transplantation Society (EBMT), published in Nature Reviews Neurology, the ideal candidate typically has:

• Relapsing-remitting MS (RRMS) with high inflammatory activity — frequent relapses, incomplete recovery, abundant new MRI lesions, or rapid disability accumulation
• Failed treatment with at least one high-efficacy DMT (such as natalizumab, alemtuzumab, or ocrelizumab)
• An Expanded Disability Status Scale (EDSS) score below 6.0 (able to walk, with or without assistance)
• Age generally under 45, though biologically fit patients above this threshold may be considered individually
• Disease duration preferably under ten years

The guidelines emphasise that AHSCT should be offered before irreversible disability sets in — the procedure can halt inflammatory disease but cannot reverse nerve damage that has already occurred.

What the clinical evidence shows

The strongest randomised evidence comes from the MIST trial (Burt et al., JAMA, 2019), which compared AHSCT against continued disease-modifying therapy in 110 patients with active RRMS. At five years, published results showed that patients in the AHSCT arm were significantly more likely to be free of disease progression, new MRI lesions, and relapses than those on continuing DMT — with disability scores improving in a proportion of AHSCT patients, something rarely seen with pharmacotherapy alone.

Broader systematic reviews and meta-analyses, including a 2024 review published in Frontiers in Immunology and indexed on PubMed/PMC, report five-year progression-free survival rates of approximately 70–80% in patients with highly active relapsing disease, with rates of “no evidence of disease activity” (NEDA) consistently higher after AHSCT than with currently available high-efficacy DMTs. For progressive forms of MS without active inflammation, published results are more modest, and the evidence base is thinner.

The ongoing BEAT-MS trial (NCT04047628) — a large US-based randomised controlled trial comparing AHSCT against best available high-efficacy therapy — is expected to provide further clarity on the magnitude of benefit when compared to the newest-generation treatments.

Benefits of AHSCT for MS

• Potential for long-term disease freedom: Many patients achieve sustained NEDA — no relapses, no new lesions, no disability progression — for years after a single procedure
• A one-time intervention: Unlike DMTs that must be taken continuously, AHSCT is a single course of treatment with the potential for durable benefit
• Disability improvement possible: A subset of patients — particularly those treated early — experience improvement in disability scores, not just stabilisation
• Reduction or elimination of ongoing DMT costs: Many patients can discontinue drug therapy after successful AHSCT

Risks and what to expect

AHSCT is a medically intensive procedure with real risks. The conditioning phase creates a period of severe immunosuppression during which the risk of infection — bacterial, viral, and fungal — is significantly elevated. The most common complications reported in published literature include febrile neutropenia, infections, and viral reactivations (such as CMV or EBV). Serious late-onset effects can include secondary autoimmune conditions and, with higher-intensity conditioning regimens, impacts on fertility.

Mortality risk from the procedure itself varies by centre experience and protocol intensity; at experienced transplant centres using intermediate-intensity regimens, published transplant-related mortality in MS cohorts has been reported below 1%. Patients should expect a total hospital stay of three to five weeks, followed by a recovery period of several months during which immune reconstitution occurs and activity is gradually restored.

Careful patient selection, pre-transplant workup, and post-transplant monitoring at an experienced centre are essential to minimising risk.

Accessing AHSCT with Medical E-Aid

AHSCT for MS is performed at a limited number of specialised haematology and neurology centres worldwide — including highly experienced programmes in Europe, Russia, and Israel — that combine established stem-cell transplant expertise with dedicated MS neurological care. Identifying the right centre for your specific disease profile, navigating the evaluation process, and coordinating travel, interpretation, and aftercare requires specialist guidance.

Medical E-Aid connects patients with leading internationally accredited centres experienced in AHSCT for autoimmune neurological conditions. Our team — supported by AI-assisted pre-screening — reviews each case to determine whether AHSCT is a realistic option, and if so, which centre and protocol best fits the patient’s clinical profile, disability level, and treatment history. We coordinate every step of the journey, from initial case review to post-procedure follow-up.

This article is for general information only and is not medical advice. AHSCT is a specialised procedure with significant risks. Treatment suitability depends on each patient’s diagnosis, disability level, treatment history, and overall health, and must be determined by qualified neurological and haematological specialists. Outcome figures are drawn from published clinical studies and may not reflect individual results.

Sources: Burt et al., JAMA 2019 (MIST trial); ECTRIMS/EBMT consensus recommendations, Nature Reviews Neurology 2024; Exploring the therapeutic potential of aHSCT in progressive MS — systematic review, Frontiers in Immunology / PubMed PMC11555148 (2024); Haematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis: Recent Advances, PubMed PMC10468923 (2023); BEAT-MS trial, ClinicalTrials.gov NCT04047628.